Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 30

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 30
---
 therefor and all regulations, resolutions, rules and interpretations issued thereunder or pursuant thereto, in each case as the same may have been or may hereafter be amended or re-enacted from time-to-time unless stated otherwise; |

| (f) | references to any agreement or document shall be to such agreement or document (together with all schedules and           
 exhibits thereto), as it may have been or may hereafter be amended, supplemented, replaced or restated from time-to-time; |

| (g) | wherever the term “includes” or “including” is used, it shall be deemed to mean  
 “includes, without limitation” or “including, without limitation”, respectively; |

| (h) | the words “the aggregate of”, “the total of”, “the sum of”, or a phrase of        
 similar meaning means “the aggregate (or total or sum), without duplication, of”; |

| (i) | the terms “made available,” “disclosed” or other terms of similar import means copies                                                                           
 of the subject materials were included in the Data Room as of 5:00 p.m. Eastern Time on the date that is two Business Days prior to the date of this Agreement; |

| (j) | all capitalized terms used in any Schedule or in the Disclosure Letter shall have the meanings ascribed to them 
 in this Agreement;                                                                                              |

| (k) | time is of the essence in the performance of the Parties’ respective obligations; and |

| (l) | unless otherwise specified, time periods within or following which any payment is to be made or act is to be                                                                                                                                    
 done, shall be calculated by excluding the day on which the period commences and including the day on which the period ends and by extending the period to the next Business Day following if the last day of the period is not a Business Day. |

- 14 -

| 1.3 | Knowledge |

Where any representation or warranty is expressly qualified by reference to knowledge of the Company, it is deemed to refer to the knowledge of Steve Forte, President, CEO and CFO, Michael Zinda, EVP, Chief Scientific Officer, Daniel Bélanger, EVP, Human Resources, Joseph O’Connell, EVP, Clinical Development & Medical Affairs, and Sandra Alves, Senior Vice President and Chief Accounting Officer, after due inquiry, but, in each case, without the requirement to make any inquiries of any Governmental Entity or persons who are not directors, officers, employees or Representatives of the Company